Quantifying Co-Oligomer Formation by Îą-Synuclein.

SAR by kinetics for drug discovery in protein misfolding diseases.

Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells.

Microfluidic deposition for resolving single-molecule protein architecture and heterogeneity.

Proteasome-targeted nanobodies alleviate pathology and functional decline in an Îą-synuclein-based Parkinson's disease model.

Multistep Inhibition of Îą-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.

Conserved S/T Residues of the Human Chaperone DNAJB6 Are Required for Effective Inhibition of Aβ42 Amyloid Fibril Formation.

Structural differences between toxic and nontoxic HypF-N oligomers.

Molecular determinants of the interaction of EGCG with ordered and disordered proteins.

Massively parallel C. elegans tracking provides multi-dimensional fingerprints for phenotypic discovery.

Kinetic barriers to Îą-synuclein protofilament formation and conversion into mature fibrils.

Cooperative Assembly of Hsp70 Subdomain Clusters.

Exploring the role of post-translational modifications in regulating Îą-synuclein interactions by studying the effects of phosphorylation on nanobody binding.

Single-Molecule Characterization of the Interactions between Extracellular Chaperones and Toxic Îą-Synuclein Oligomers.

Basosquamous Carcinoma: A Single Centre Clinicopathological Evaluation and Proposal of an Evidence-Based Protocol.